| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1101248984 |
| P356 | DOI | 10.1186/S13045-018-0576-6 |
| P932 | PMC publication ID | 5830080 |
| P698 | PubMed publication ID | 29486795 |
| P50 | author | Andrea Mancini | Q57054269 |
| Loredana Cristiano | Q92362984 | ||
| P2093 | author name string | Antonella Vetuschi | |
| Yi Chen | |||
| Claudio Festuccia | |||
| Francesco Marampon | |||
| Simona Pompili | |||
| Giovanni Luca Gravina | |||
| Vincenzo Tombolini | |||
| Flora Vitale | |||
| Thomas Mehrling | |||
| Simona Delle Monache | |||
| Alessandro Colapietro | |||
| P2860 | cites work | Role of PHLPP1 in inflammation response: Its loss contributes to gliomas development and progression | Q38786799 |
| Cyclooxygenase-2 inhibitor prevents radiation-enhanced infiltration of F98 glioma cells in brain of Fischer rat. | Q38882354 | ||
| Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. | Q39107568 | ||
| Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway | Q39149627 | ||
| PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer | Q39178894 | ||
| The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis | Q39266259 | ||
| An in vivo patient-derived model of endogenous IDH1-mutant glioma | Q39429029 | ||
| HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin. | Q39999407 | ||
| Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine | Q40390390 | ||
| Bendamustine: a novel cytotoxic agent for hematologic malignancies | Q40407656 | ||
| Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). | Q40445929 | ||
| The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101. | Q40933121 | ||
| Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair | Q41088379 | ||
| The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. | Q41316676 | ||
| Incision at O6-methylguanine:thymine mispairs in DNA by extracts of human cells | Q41604353 | ||
| Molecular dissection of the valproic acid effects on glioma cells | Q41809551 | ||
| Sensitivity to temozolomide in brain tumor initiating cells | Q42425950 | ||
| The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. | Q48121335 | ||
| Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors | Q48695471 | ||
| Efficacy of rapamycin against glioblastoma cancer stem cells | Q49022095 | ||
| Sensitive LC-MS/MS Method for the Simultaneous Determination of Bendamustine and its Active Metabolite, γ-Hydroxybendamustine in Small Volume Mice and Dog Plasma and its Application to a Pharmacokinetic Study in Mice and Dogs. | Q50611300 | ||
| Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. | Q55480771 | ||
| Mean inactivation dose: a useful concept for intercomparison of human cell survival curves | Q71405944 | ||
| Epigenetic treatment of solid tumours: a review of clinical trials | Q26773803 | ||
| Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair | Q26863429 | ||
| Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites | Q27011795 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma | Q28286168 | ||
| Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression | Q28550138 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma | Q30300986 | ||
| Salvage therapy with single agent bendamustine for recurrent glioblastoma | Q33395579 | ||
| Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. | Q33402978 | ||
| Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial | Q33439379 | ||
| Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models. | Q33728180 | ||
| Clinical value of CD133 and nestin in patients with glioma: a population-based study | Q34028947 | ||
| Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or ritux | Q34415486 | ||
| Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. | Q34480576 | ||
| Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells | Q36026945 | ||
| Reversion of malignant phenotypes of human glioblastoma cells by β-elemene through β-catenin-mediated regulation of stemness-, differentiation- and epithelial-to-mesenchymal transition-related molecules | Q36273891 | ||
| A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells | Q36299600 | ||
| MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. | Q36552798 | ||
| Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors | Q36618220 | ||
| NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. | Q36735911 | ||
| Suberoylanilide hydroxamic acid represses glioma stem-like cells. | Q37423898 | ||
| Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases | Q37544152 | ||
| The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma | Q37567174 | ||
| HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells | Q37683049 | ||
| Drug combinations with proteasome inhibitors in antitumor therapy | Q38062570 | ||
| Epigenetics in radiotherapy: where are we heading? | Q38214881 | ||
| How to train glioma cells to die: molecular challenges in cell death | Q38626416 | ||
| The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. | Q38699394 | ||
| HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells | Q38710507 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 32 | |
| P577 | publication date | 2018-02-27 | |
| P1433 | published in | Journal of Hematology & Oncology | Q15724593 |
| P1476 | title | The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma | |
| P478 | volume | 11 |
| Q52655651 | Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. |
| Q64097434 | Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3 |
| Q57107038 | The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge |
Search more.